Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe.
dc.contributor.author | Reichardt, P | |
dc.contributor.author | Leahy, Michael G | |
dc.contributor.author | Garcia Del Muro, X | |
dc.contributor.author | Ferrari, S | |
dc.contributor.author | Martin, J | |
dc.contributor.author | Gelderblom, H | |
dc.contributor.author | Wang, J | |
dc.contributor.author | Krishna, A | |
dc.contributor.author | Eriksson, J | |
dc.contributor.author | Staddon, A | |
dc.contributor.author | Blay, J | |
dc.date.accessioned | 2014-04-10T11:15:21Z | |
dc.date.available | 2014-04-10T11:15:21Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) Study. 2012, 2012:740279 Sarcoma | en |
dc.identifier.issn | 1369-1643 | |
dc.identifier.pmid | 22550425 | |
dc.identifier.doi | 10.1155/2012/740279 | |
dc.identifier.uri | http://hdl.handle.net/10541/315625 | |
dc.description.abstract | The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Sarcoma | en |
dc.title | Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe. | en |
dc.type | Article | en |
dc.contributor.department | Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, 15526 Bad Saarow, Germany | en |
dc.identifier.journal | Sarcoma | en |
html.description.abstract | The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease. |